Teva Pharmaceutical to acquire NuPathe - MarketLine Financial Deals

Teva Pharmaceutical to acquire NuPathe

Teva Pharmaceutical to acquire NuPathe - MarketLine Financial Deals
Teva Pharmaceutical to acquire NuPathe
Published Jan 06, 2014
5 pages — Published Jan 06, 2014
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Teva Pharmaceutical Industries, Ltd., an Israel-based pharmaceutical company, has made an offer to acquire NuPathe, Inc., a US-based pharmaceutical company, at a price of $3.65 per share in cash.

  
Source:
Document ID
MA144550_140120
Country
Country
Ticker
TEVA=IL
Ticker
PATH=US
Company
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Teva Pharmaceutical to acquire NuPathe" Jan 06, 2014. Alacra Store. Dec 03, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Teva-Pharmaceutical-to-acquire-NuPathe-2052-100251>
  
APA:
MarketLine Financial Deals. (2014). Teva Pharmaceutical to acquire NuPathe Jan 06, 2014. New York, NY: Alacra Store. Retrieved Dec 03, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Teva-Pharmaceutical-to-acquire-NuPathe-2052-100251>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.